We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas.
- Authors
SONNENBLICK, AMIR; ELEYAN, FERAS; PERETZ, TAMAR; OSPOVAT, INNA; MERIMSKY, OFER; SELLA, TAMAR; PEYLAN-RAMU, NILI; KATZ, DANIELA
- Abstract
A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. Data were collected on all patients with advanced non-resectable STS who were treated with a fixed dose 700 mg/m2 gemcitabine in combination with 70 mg/m2 paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40-70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression- free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.
- Subjects
SARCOMA; SOFT tissue tumors; DOXORUBICIN; PACLITAXEL; CANCER chemotherapy; MYELOSUPPRESSION
- Publication
Molecular & Clinical Oncology, 2015, Vol 3, Issue 4, p89
- ISSN
2049-9450
- Publication type
Academic Journal
- DOI
10.3892/mco.2015.545